Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.

Tencent has led a $64m series D round for the healthtech developer, whose shareholders already include SoftBank.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

Ghent University-founded rapid diagnostic test developer Antelope DX picked up Whitefund and existing investors to bring its funding total to $16.6m.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.